Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

NPPA fixes retail prices of 39 new drug formulations

Дата публикации: 11-07-2026 06:26:47

The notification issued on July 8 is a retail price fixation order for new drug formulations under DPCO, 2013, not a price reduction order

Основное содержимое страницы с новостью.

The (NPPA) has fixed the retail prices of 39 new drug formulations under the Drugs (Prices Control) Order (DPCO), 2013. The formulations cover a wide range of medicines, including those used to treat hypertension, diabetes, HIV, heart disease and eye infections, with the aim of making them more affordable for patients.

The notification was issued on July 8. It is a retail price fixation order for new drug formulations under the DPCO, 2013, and not a price reduction order.

Among the medicines included, Amlodipine + Bisoprolol + Telmisartan Tablets, used for the treatment of hypertension (high blood pressure), have been fixed at ₹14.74 per tablet.

The retail price of Nepafenac + Moxifloxacin Ophthalmic Solution, an eye drop used after eye surgery and for the treatment of bacterial eye infections, has been fixed at ₹68.64 per ml.Similarly, Clopidogrel + Aspirin + Atorvastatin Capsules, which are used to reduce the risk of heart attack and stroke, have been priced at ₹6.37 per capsule.

The NPPA also reiterated that retailers and dealers are required to prominently display the price lists provided by manufacturers. Quoting the DPCO, 2013, the authority said, "As per para 24(4) of DPCO, 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same."

The notification further stated that if any manufacturer or marketing company fails to comply with the notified retail prices, it will be liable to deposit the overcharged amount along with applicable interest.

"In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955," the notification stated.

Published on July 11, 2026

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Govt notifies 30% cap on trade margins on 137 cancer drugs, new prices from November 9017.3118-10-2026
2Минздрав зарегистрировал предельные отпускные цены на лекарственные препараты от COVID-190016-10-2020
3Новый КоАП предполагает штрафы до 300 тыс. рублей за отсутствие маркировки лекарств0002-06-2020
4Кабмин утвердил правила ограничения отпускных цен на лекарства0005-09-2020
5Ветеринарам утвердили новые нормы для психотропных препаратов0529-06-2026
6Росздравнадзор рассказал о росте цен на жизненно необходимые препараты0009-09-2019
7Фавипиравир включат в перечень жизненно необходимых важнейших лекарств0018-09-2020
8ФАС внесла законопроект о запрете объединения закупки и отпуска лекарств в одном лоте0005-10-2018
9Путин подписал закон о дистанционной продаже лекарств0003-04-2020
10Минпромторг изучает возможность внедрения фиксированной наценки аптеками на лекарства0012-08-2019

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.thehindubusinessline.com.